0.68
-0.003(-0.44%)
Currency In USD
| Previous Close | 0.68 |
| Open | 0.67 |
| Day High | 0.69 |
| Day Low | 0.63 |
| 52-Week High | 3.85 |
| 52-Week Low | 0.54 |
| Volume | 1.59M |
| Average Volume | 1.38M |
| Market Cap | 7.19M |
| PE | -0.19 |
| EPS | -3.5 |
| Moving Average 50 Days | 0.71 |
| Moving Average 200 Days | 1.57 |
| Change | -0 |
If you invested $1000 in GT Biopharma, Inc. (GTBP) since IPO date, it would be worth $0.8 as of January 10, 2026 at a share price of $0.677. Whereas If you bought $1000 worth of GT Biopharma, Inc. (GTBP) shares 5 years ago, it would be worth $2.7 as of January 10, 2026 at a share price of $0.677.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 14, 2025 2:00 PM GMT
Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumor
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GlobeNewswire Inc.
Oct 08, 2025 1:00 PM GMT
The Company is well on track with Phase 1 enrollment now that both patients in Cohort 3 have successfully initiated treatment with no evidence of dose-limiting toxicities or tolerability concerns to date The first patient in Cohort 3 has shown promis
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GlobeNewswire Inc.
Oct 06, 2025 1:00 PM GMT
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer